TL;DR
This review explores the intricate link between viral infections and dry eye disease (DED), highlighting how various viruses can trigger ocular surface inflammation and lacrimal gland dysfunction, leading to DED. It synthesizes current knowledge on the mechanisms, diagnostic approaches, and therapeutic strategies for viral infection-associated DED, emphasizing the need for further research into these complex interactions.
What Problem Does This Paper Address?
Dry eye disease (DED) is a prevalent and multifactorial condition affecting millions worldwide. While numerous factors are known to contribute to DED, such as environmental factors, aging, and systemic diseases, the specific role of viral infections in its pathogenesis has been an area of growing interest. This paper addresses the gap in understanding how viral infections, ranging from common viruses to emerging threats like SARS-CoV-2, can directly or indirectly cause or exacerbate DED. It aims to consolidate existing research on the mechanisms by which viruses impact the ocular surface and lacrimal glands, the diagnostic challenges, and the current and potential future therapeutic interventions for this specific subtype of DED.
Methods
This paper is a comprehensive review article. The authors synthesized information from a broad range of published research, including original studies, case reports, and other review articles. They systematically analyzed the literature to identify viruses implicated in DED, the proposed mechanisms of pathogenesis, diagnostic methods used to identify viral involvement, and therapeutic strategies employed or investigated. The review draws upon epidemiological data, immunological studies, and molecular mechanisms to build a cohesive narrative.
Datasets
Not discussed in the paper. This is a review article that synthesizes existing research rather than presenting new experimental data or introducing novel datasets.
Key Insights and Ideas
- Viruses are significant, often overlooked, contributors to DED: Beyond well-known causes, a diverse range of viruses can directly infect ocular tissues or trigger systemic immune responses that manifest as DED.
- Multiple viral mechanisms lead to DED: Viruses can cause DED through direct damage to ocular surface cells (corneal epithelial cells, conjunctival goblet cells), inflammation of the lacrimal gland (LG), disruption of tear film stability, and induction of autoimmune responses.
- SARS-CoV-2 and DED: The COVID-19 pandemic has brought increased attention to DED, with mask-wearing contributing to "mask-associated dry eye" (MADE) and the virus itself potentially affecting the ocular surface via ACE2 receptors.
- Diverse viral culprits: The review details the roles of specific viruses like HIV, EBV, HCV, HTLV-1, and SARS-CoV-2 in DED pathogenesis, each with unique mechanisms and ocular manifestations.
- Diagnostic challenges: Identifying viral involvement in DED can be complex, often requiring advanced molecular techniques like PCR in addition to standard DED diagnostic tools.
- Therapeutic landscape is evolving: While current treatments often involve symptomatic relief (artificial tears, anti-inflammatories), there's a growing need for targeted antiviral therapies and immunomodulatory approaches for viral-associated DED.
Key Results
- Prevalence: Studies indicate a significant prevalence of DED in various populations, with viral infections contributing to a notable subset. For instance, a survey found 7.90% of participants had MADE.
- Viral Mechanisms: Viruses activate innate immune pathways, leading to inflammation, apoptosis, and reduced cell proliferation. Specific examples include SARS-CoV-2 utilizing ACE2 receptors and activating NF-κB, and EBV infecting corneal epithelial cells via NF-κB.
- Ocular Manifestations: Viral infections can lead to reduced tear volume, ocular surface inflammation, corneal damage, conjunctival changes (e.g., goblet cell loss), and lacrimal gland dysfunction.
- Treatment Efficacy: While some treatments like ozonated oil have shown promise in reducing SARS-CoV-2 infection on the ocular surface, and combined antiretroviral therapy (cART) improves ocular findings in HIV patients, a definitive cure for viral-associated DED remains elusive.
Limitations and Future Work
- Limitations:
- The exact cellular and molecular mechanisms of DED caused by HIV and HTLV-1 remain unclear and require further investigation.
- While cell and animal models are being developed, there is a need for more robust models to fully explore the pathogenesis of viral infection-associated DED.
- Current therapeutic strategies for viral-associated DED are often suboptimal, relying heavily on symptomatic relief.
- Future Work:
- Further research is needed to elucidate the precise mechanisms by which viruses like HIV and HTLV-1 contribute to DED.
- Development of more effective and targeted antiviral therapies and immunomodulatory treatments for viral infection-associated DED is crucial.
- Continued development and utilization of cell and animal models are essential for understanding pathogenesis and testing new therapies.
- There is a need for a deeper and wider understanding of the direct relationship between viral infections and DED to enable timely and accurate diagnosis and effective treatment.
Summary updated